<DOC>
	<DOCNO>NCT03026023</DOCNO>
	<brief_summary>This proof concept , single center study donation HCV-positive heart HCV negative recipient patient , preemptive , interventional treatment 12-16 week grazoprevir elbasvir ( without ribavirin ) prevent HCV transmission upon transplantation .</brief_summary>
	<brief_title>Preemptive Zepatier Treatment Donor HCV Positive Recipient HCV Negative Cardiac Transplant</brief_title>
	<detailed_description>Phase 1 study single case study one subject enrol . Once safety demonstrate HCV infection transmission show prevented protocol , study expand 10 additional patient . Patients select base diminished likelihood receive heart waitlist within period would likely succumb severe comorbidities . This determined part use patient 's listing status ( 1A , 1B , 2 ) clinical judgment , Seattle Heart Failure Model .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Recipient Age â‰¥ 18 year Serum ALT within normal limit history liver disease Lack sensitization ( i.e . PRA &lt; 20 % ) would expect result high likelihood need aggressive immunosuppression treat rejection Sensitization ( i.e . PRA &gt; 20 % ) Any liver disease recipient Albumin &lt; 3g/dl platelet count &lt; 75 x 103/mL Need dual organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Heart Transplant</keyword>
	<keyword>Cardiac Transplant</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Zepatier</keyword>
</DOC>